NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- 1 March 2021
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 19 (3), 254-266
- https://doi.org/10.6004/jnccn.2021.0013
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.This publication has 52 references indexed in Scilit:
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation SequencingJournal of Clinical Oncology, 2018
- Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2018
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2017
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison ProjectJournal of Thoracic Oncology, 2017
- The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancerScientific Reports, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisClinical Cancer Research, 2016
- Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain MetastasisJournal of Clinical Oncology, 2016
- Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIsJournal of Thoracic Oncology, 2015
- Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium ExperienceJournal of Thoracic Oncology, 2015